idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
As part of a clinical trial, the National Center for Tumor Diseases (NCT/UCC) Dresden is now offering patients with pancreatic cancer (pancreatic carcinoma) the opportunity to participate in an innovative treatment using a personalized mRNA-based cancer vaccine following surgery.
Pancreatic cancer is one of the deadliest types of cancer worldwide. Despite surgical removal of the tumor, most patients experience a recurrence, and even with additional chemotherapy, only one in three to four patients survives five years after surgery. "These alarming figures highlight the urgent need for new treatment approaches for pancreatic cancer," explains PD Dr. Adrian Seifert, surgeon and local co-investigator of the study.
The mRNA cancer vaccine, Autogene Cevumeran, developed by BioNTech and Genentech, is based on tumor-specific protein fragments (neoantigens) and aims to activate the body's immune system to specifically target any remaining cancer cells. In a Phase 1 study (NCT04161755) led by Prof. Vinod Balachandran at Memorial Sloan Kettering Cancer Center in New York, a strong and sustained T-cell immune response was triggered in half of the patients treated with Autogene Cevumeran after surgery. These patients had a significantly reduced risk of relapse.
“As NCT/UCC Dresden, we are very proud to be the only center in Saxony participating in the international Phase 2 study,” says Prof. Jürgen Weitz, Managing Director of the NCT/UCC and Director of the Department of Visceral, Thoracic and Vascular Surgery. Prof. Gunnar Folprecht, oncologist and local principal investigator, adds: “We are very pleased to offer this promising treatment option. The mRNA vaccine is an important step toward personalized cancer medicine, tailored to the specific characteristics of each individual tumor. With this approach, we may be able to significantly reduce the high risk of recurrence after surgery. Participation in the study is only possible in close temporal proximity to the surgery. This highlights the need for close collaboration between medical specialties.”
IMCODE003 Study (NCT05968326): A study of the efficacy and safety of adjuvant Autogene Cevumeran plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX alone in participants with resected PDAC (NCT05968326)
The study is investigating the efficacy and safety of the vaccine in combination with the PD-L1 checkpoint inhibitor Atezolizumab and chemotherapy (mFOLFIRINOX), compared to chemotherapy alone (mFOLFIRINOX) immediately after surgery in patients who have not yet received chemotherapy or radiotherapy and who show no evidence of metastasis. Interested patients and physicians can contact the NCT/UCC study office for further information and to inquire about participation.
Anne-Stephanie Vetter
Staff Unit Public Relations of Carl Gustav Carus Faculty of Medicine
at TUD Dresden University of Technology
National Center for Tumor Diseases (NCT/UCC) Dresden
Tel.: +49 (0) 351 458 17903
Email: anne-stephanie.vetter@tu-dresden.de
Prof. Dr. med. Gunnar Folprecht
Department of Internal Medicine I
University Hospital Carl Gustav Carus, TU Dresden
PD Dr. med. Adrian Seifert
Department of Visceral, Thoracic, and Vascular Surgery
University Hospital Carl Gustav Carus, TU Dresden
NCT/UCC Study Office: oncostudy@ukdd.de
IMCODE003 Study (NCT05968326): A study of the efficacy and safety of adjuvant Autogene Cevumeran plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX alone in participants with resected PDAC (NCT05968326)
http://www.nct-dresden.de The National Center for Tumor Diseases (NCT/UCC) Dresden is a joint institution involving the German Cancer Research Center (German abbreviation: DKFZ), the Faculty of Medicine at TU Dresden, the Carl Gustav Carus University Hospital Dresden and the Helmholtz-Zentrum Dresden-Rossendorf (HZDR). Patients are research partners on an equal footing.
Merkmale dieser Pressemitteilung:
Journalisten, Wissenschaftler
Ernährung / Gesundheit / Pflege, Medizin
überregional
Forschungsprojekte, Wissenschaftliche Publikationen
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
